These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34899063)

  • 1. Can R&D investment reduce the impact of COVID-19 on firm performance?-Evidence from India.
    Biswas S
    J Public Aff; 2021 Oct; ():e2773. PubMed ID: 34899063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Impact of Firm's Unethical Behavior in Investment Decisions Among Young Investors in China.
    Tang X; Yu K; Yu W
    Psychol Res Behav Manag; 2022; 15():3427-3443. PubMed ID: 36466762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How R&D intensive firms react to the COVID-19 pandemic: Evidence from a quasi-natural experiment.
    Pham THL; Nguyen DHT; Chu VT; Nguyen KD; Pham BT
    Heliyon; 2023 Sep; 9(9):e19329. PubMed ID: 37662736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dark side of globalization: Evidence from the impact of COVID-19 on multinational companies.
    Guedhami O; Knill A; Megginson WL; Senbet LW
    J Int Bus Stud; 2022; 53(8):1603-1640. PubMed ID: 36093034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leadership in a pandemic: Do more able managers keep firms out of trouble?
    Nguyen HT; Pham MH; Truong C
    J Behav Exp Finance; 2023 Mar; 37():100781. PubMed ID: 36568125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative evidence on the impact of the COVID-19 outbreak and vaccine discovery on the global transportation industry.
    Maneenop S; Kotcharin S
    Transp Res Interdiscip Perspect; 2023 Jan; 17():100741. PubMed ID: 36618962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Firms' COVID-19 Pandemic Exposure and Corporate Cash Policy: Evidence from China.
    He Z; Suardi S; Wang K; Zhao Y
    Econ Model; 2022 Nov; 116():105999. PubMed ID: 36032988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CEO Overconfidence, Corporate Governance, and R&D Smoothing in Technology-Based Entrepreneurial Firms.
    Huang Y; Wang X; Li Y; Yu X
    Front Psychol; 2022; 13():944117. PubMed ID: 35910989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Will the Volume-Based Procurement Policy Promote Pharmaceutical Firms' R&D Investment in China? An Event Study Approach.
    Hu Y; Chen S; Qiu F; Chen P; Chen S
    Int J Environ Res Public Health; 2021 Nov; 18(22):. PubMed ID: 34831803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19, ESG investing, and the resilience of more sustainable stocks: Evidence from European firms.
    Cardillo G; Bendinelli E; Torluccio G
    Bus Strategy Environ; 2022 Jun; ():. PubMed ID: 35942337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Research on the Crisis Spillover Effect of Food Safety Incidents on Competitive Firms: The Influence of Political Connections and Charitable Donations.
    Xiang R; Wang M; Lin L; Wu D
    Front Public Health; 2021; 9():766385. PubMed ID: 34900911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. R&D investment and financial performance in EU countries: The role of shareholder protection and creditor rights in renewable energy firms.
    Karlilar S; Tarzibashi OFF
    Environ Sci Pollut Res Int; 2023 Dec; 30(59):124170-124181. PubMed ID: 37996591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microcap pharmaceutical firms: linking drug pipelines to market value.
    Beach R
    J Health Care Finance; 2012; 39(2):82-92. PubMed ID: 23971143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can corporate social responsibility protect firm value during the COVID-19 pandemic?
    Qiu SC; Jiang J; Liu X; Chen MH; Yuan X
    Int J Hosp Manag; 2021 Feb; 93():102759. PubMed ID: 36919172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the COVID-19 pandemic: Evidence from the U.S. restaurant industry.
    Song HJ; Yeon J; Lee S
    Int J Hosp Manag; 2021 Jan; 92():102702. PubMed ID: 33024347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Emotional Harassment on Firm's Value.
    Choi YH; Park HJ; Choi SJ
    Front Psychol; 2018; 9():2333. PubMed ID: 30564166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Corporate Governance on Research and Development Investment in the Pharmaceutical Industry in South Korea.
    Lee M
    Osong Public Health Res Perspect; 2015 Aug; 6(4):249-55. PubMed ID: 26473092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mediating factors and spillover effects of foreign direct investment : Evidence from Indian manufacturing firms.
    Ranjan Mishra B; Satpathy LD; Kumar Jena P; Dehury T
    Heliyon; 2024 Jun; 10(12):e32519. PubMed ID: 39183869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fiscal Stimulus and Firms' Sales and Capital Expenditure During the Global Financial Crisis.
    Correa-Caro C; Medina L; Poplawski-Ribeiro M; Sutton B
    Comp Econ Stud; 2021; 63(3):489-535. PubMed ID: 34366561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between corporate social responsibility, environmental investments and financial performance: evidence from manufacturing companies.
    Shabbir MS; Wisdom O
    Environ Sci Pollut Res Int; 2020 Nov; 27(32):39946-39957. PubMed ID: 32797400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.